202409-82-3

Basic information

• Product Name: 2-(Benzyloxy)-3-bromo-5-chloropyridine
• Synonyms: 2-(Benzyloxy)-3-bromo-5-chloropyridine
• CAS NO: 202409-82-3
• Molecular Formula: C₁₂H₉BrClNO
• Molecular Weight: 298.56296
• Mol File: 202409-82-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 345.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.527±0.06 g/cm3(Predicted)
• PKA: -0.74±0.32(Predicted)
• CAS DataBase Reference: 2-(Benzyloxy)-3-bromo-5-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Benzyloxy)-3-bromo-5-chloropyridine(202409-82-3)
• EPA Substance Registry System: 2-(Benzyloxy)-3-bromo-5-chloropyridine(202409-82-3)

Safety Data

• Hazardous Substances Data: 202409-82-3(Hazardous Substances Data)

Usage

Structure

Pyridine derivative with a benzyl ether group and bromine and chlorine substituents

Usage

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Potential

Can be used in the development of new drugs and in research studies

Safety

Handle with care and follow proper safety protocols due to potential hazards

Upstream product

• 138006-41-4 3-bromo-2,5-dichloropyridine 
• 100-51-6 benzyl alcohol 
• 4214-79-3 5-chloro-2-pyridinol 
• 137628-16-1 3-bromo-5-chloro-2-hydroxypyridine 
• 100-39-0 benzyl bromide 

Downstream Products

• 690261-51-9 3-(2-bromo-phenyl)-5-chloro-2-(benzyloxy)-pyridine 
• 745050-28-6 2-benzoyloxy-5-chloro-3-[4-(methylthio)phenyl]pyridine 
• 442692-43-5 2-benzyloxy-5-chloro-3-(4-methoxyphenyl)-pyridine 
• 202409-84-5 2-Benzyloxy-5-chloro-3-(4-methylsulfonyl)phenylpyridine 

Relevant articles and documents

HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, L1,

PHENYL COMPOUNDS

Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R, R, R, R, R, and R are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease

The instant invention provides a drug combination comprised of an HMG-CoA reductase inhibitor in combination with a COX-2 inhibitor, which is useful for treating, preventing, and/or reducing the risk of developing atherosclerosis and atherosclerotic disease events.